Briellyn

Endometriosis, Low Testosterone, Osteoporosis + 16 more
Treatment
20 Active Studies for Briellyn

What is Briellyn

NorethisteroneThe Generic name of this drug
Treatment SummaryNorethisterone, also known as norethindrone, is a type of hormone therapy used to treat menstrual irregularities, endometriosis, and for contraception. It was developed in 1951 and approved for contraception in 1962. Norethisterone works by mimicking the effects of progesterone, a hormone naturally produced by the body, and is more potent than progesterone. It is available in combination with estrogen derivatives for use in hormone replacement therapy.
Neconis the brand name
image of different drug pills on a surface
Briellyn Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Necon
Norethisterone
1967
347

Effectiveness

How Briellyn Affects PatientsNorethisterone is a form of medication used to prevent pregnancy or treat other hormone-related issues such as menopause and endometriosis. It is a more powerful form of the hormone progesterone and works in the pelvic area to alter the cervical and endometrial functions and stops certain hormones from maturing eggs and releasing them from the ovaries. Taking norethisterone slightly increases the risk of developing breast cancer, so patients should be aware of this risk and should check their breasts regularly.
How Briellyn works in the bodyNorethisterone works by binding to progesterone receptors in the body, which causes a variety of changes. In the reproductive tract, it increases the viscosity of cervical mucus to prevent sperm from entering, and changes the endometrium to make it inhospitable to implantation. It also lowers the levels of hormones that help with ovulation and follicular development, preventing pregnancy. When used as part of hormone replacement therapy, it helps suppress the growth of the endometrium and reduces the risk of endometrial cancer. Lastly, norethisterone has a low affinity for other hormone receptors, and is

When to interrupt dosage

The suggested dosage of Briellyn is contingent upon the diagnosed condition, for example Atrophic, Fracture and Hormone Replacement Therapy. The quantity of dosage is contingent upon the technique of delivery (e.g. Oral or Tablet) showcased in the table beneath.
Condition
Dosage
Administration
Estrogen Deprivation Symptoms
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Osteoporosis
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Osteoporosis, Postmenopausal
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Hot flashes
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Fracture
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
hypoestrogenism
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Atrophic
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Birth Control
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Therapeutic procedure
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Low Testosterone
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Endometriosis
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Menopause
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Oral Contraceptives
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Endometriosis
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Primary Ovarian Insufficiency
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Hormonal Contraception
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
female castration
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Hormone Replacement Therapy
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Capsule - Oral, Capsule, Intramuscular; Oral; Topical
Vasomotor System
0.014 mg/hour, , 0.025 mg/hour, 0.5 mg, 0.1 mg, 5.0 mg, 1.0 mg, 0.35 mg, 1.5 mg, 0.8 mg, 2.7 mg, 4.8 mg, 0.75 mg, 0.4 mg, 2.25 mg, 30.0 mg, 3.0 mg
, Patch, extended release, Patch, extended release - Transdermal, Transdermal, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Kit, Kit - Oral, Patch, Tablet, chewable, Tablet, chewable - Oral, Patch - Transdermal, Capsule - Oral, Capsule, Intramuscular; Oral; Topical

Warnings

Briellyn Contraindications
Condition
Risk Level
Notes
Liver Diseases
Do Not Combine
Thrombophilia
Do Not Combine
Vaginal Hemorrhage
Do Not Combine
Malignant Neoplasms
Do Not Combine
Benign hepatic neoplasm
Do Not Combine
Breast Cancer
Do Not Combine
Thromboembolism
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Norethisterone may interact with Pulse Frequency
There are 20 known major drug interactions with Briellyn.
Common Briellyn Drug Interactions
Drug Name
Risk Level
Description
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Norethisterone.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Norethisterone.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Norethisterone.
Clomipramine
Major
The metabolism of Clomipramine can be increased when combined with Norethisterone.
Copanlisib
Major
The metabolism of Copanlisib can be decreased when combined with Norethisterone.
Briellyn Toxicity & Overdose RiskThe lowest toxic dose of oral contraceptives in mice is 6g/kg and in human women is 42mg/kg. So far, there have been no serious reports of ill effects from overdosing on oral contraceptives. Symptoms of overdosing may include strong nausea and vomiting.
image of a doctor in a lab doing drug, clinical research

Briellyn Novel Uses: Which Conditions Have a Clinical Trial Featuring Briellyn?

160 active clinical trials are being conducted to evaluate the potential of Briellyn in providing Birth Control, Alleviating Atrophic Symptoms and Increasing Testosterone levels.
Condition
Clinical Trials
Trial Phases
Birth Control
22 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Early Phase 1, Phase 2
Oral Contraceptives
1 Actively Recruiting
Not Applicable
Endometriosis
27 Actively Recruiting
Early Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4
Osteoporosis
27 Actively Recruiting
Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2
Low Testosterone
6 Actively Recruiting
Phase 4, Phase 2, Phase 1
Endometriosis
2 Actively Recruiting
Phase 4, Not Applicable
Hot flashes
19 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Early Phase 1, Phase 3
Estrogen Deprivation Symptoms
0 Actively Recruiting
Osteoporosis, Postmenopausal
0 Actively Recruiting
female castration
0 Actively Recruiting
Atrophic
4 Actively Recruiting
Phase 4, Not Applicable
Hormone Replacement Therapy
0 Actively Recruiting
Hormonal Contraception
0 Actively Recruiting
hypoestrogenism
1 Actively Recruiting
Phase 4
Fracture
0 Actively Recruiting
Vasomotor System
0 Actively Recruiting
Primary Ovarian Insufficiency
0 Actively Recruiting
Therapeutic procedure
0 Actively Recruiting
Menopause
0 Actively Recruiting

Briellyn Reviews: What are patients saying about Briellyn?

1Patient Review
11/14/2011
Briellyn for Birth Control
This treatment caused me to experience breakthrough bleeding and vaginal itching, which was overall very uncomfortable.

Patient Q&A Section about briellyn

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Briellyn generic for?

"Briellyn 28-Day provides a continuous regimen of oral contraception for 21 days, consisting of light peach tablets of norethindrone and ethinyl estradiol, followed by 7 white to off-white tablets of inert ingredients. This regimen will be available from May 1, 2022."

Answered by AI

Can missing one pill make you bleed?

"If you forget to take your birth control pill even once, you might experience breakthrough bleeding or spotting. If you forget to take your pill more than once in a month, you'll need to use a second form of birth control (like a condom) to prevent pregnancy. You'll need to use this second form of birth control until you start your next pill pack."

Answered by AI

Is it normal to not get a period on the pill?

"If you go for several months without having a period, you may have something called post-pill amenorrhea. The pill stops your body from making the hormones involved in ovulation and menstruation. When you stop taking the pill, your body might need some time to start making those hormones again."

Answered by AI

How effective is Blisovi birth control?

"About 1-4% of women may get pregnant within the first year of using Blisovi 24 Fe, based on the results from the clinical study. The following chart demonstrates the chances of getting pregnant for women who use different methods of birth control."

Answered by AI

Clinical Trials for Briellyn

Image of Erevna Innovations Inc. in Montreal, Canada.

Sculptra + Restylane for Post-Menopausal Skin Concerns

40 - 65
Female
Montreal, Canada
The post-menopausal state is marked by a sharp decline in estrogen, leading to significant structural and functional changes in the skin, including collagen loss, dryness, thinning, and reduced elasticity. To address these concerns, aesthetic injectables products such as Sculptra® Aesthetic (poly-L-lactic-acid \[PLLA- SCA\]) and Restylane Skinboosters®\[HASBV\] (small-particle hyaluronic acid - SP-HA) can be used. PLLA-SCA stimulates collagen production via cellular activation (biostimulator), gradually improving dermal structure. HASBV enhances hydration, elasticity, and skin texture when injected under the skin. Considering that hydration and laxity represent the primary aesthetic concerns in this patient population. Targeted treatment with SP-HA (HASBV) to improve hydration and PLLA-SCA to address laxity have been shown to produce significant clinical outcomes by directly addressing these key dermal deficiencies. This approach forms the basis of the current study.
Phase 4
Recruiting
Erevna Innovations Inc.Andreas Nikolis, MD, PhD
Image of University Hospitals Cleveland Medical Center in Cleveland, United States.

Ketamine for Pelvic Pain

18 - 89
Female
Cleveland, OH
The purpose of this research study is to see if ketamine infusion during surgery can decrease pain after surgery. Ketamine is a medication commonly used as part of anesthesia during surgery and is approved by the US FDA. Patients will be randomized to either receive standard anesthesia with OR without ketamine. The surgical procedure will be the same regardless of which group patients are randomized to. After surgery, patients will be asked to rate their pain in the post-operative observation unit and at their two-week post-operative visit. No additional visits are required for participation in this study. The investigators estimate the surveys will take approximately 10 minutes to complete.
Phase 4
Waitlist Available
University Hospitals Cleveland Medical CenterMorgan Cheeks, MD
Have you considered Briellyn clinical trials? We made a collection of clinical trials featuring Briellyn, we think they might fit your search criteria.Go to Trials
Image of ICON Early Phase Services, LLC_Clinic San Antonio in San Antonio, United States.

Follitropin Alfa for Male Infertility

18 - 45
Male
San Antonio, TX
The purpose of this study is to assess the bioequivalence of Test and Reference in healthy downregulated male participants. This is a 2-sequence, 2-period study using the following treatment sequences across Study Periods 1 and 2. At the end of the first Downregulation period (DR1), eligible participants will be randomly assigned to 1 of the 2 treatment sequences: Sequence 1: Test - Reference Sequence 2: Reference - Test Where, Test = follitropin alfa (solution for injection in prefilled pen), and Reference = follitropin alfa (powder and diluent for solution for injection in vial). The total duration of the study will be up to approximately 9 weeks.
Phase 1
Recruiting
ICON Early Phase Services, LLC_Clinic San AntonioMedical ResponsibleEMD Serono Research & Development Institute, Inc.
Have you considered Briellyn clinical trials? We made a collection of clinical trials featuring Briellyn, we think they might fit your search criteria.Go to Trials
Image of Alethios, Inc. in San Francisco, United States.

NettleEndo for Endometriosis

22 - 45
Female
San Francisco, CA
The goal of this clinical trial is to learn if a wearable brain stimulation device called NettleEndo can reduce chronic pelvic pain and improve wellbeing in women with endometriosis. The study also aims to assess the safety and usability of the device when used at home over several months. The main questions it aims to answer are: 1. Does at-home transcranial direct current stimulation (tDCS) reduce daily pain intensity in women with endometriosis? 2. Does the device also improve mood and sleep quality? Researchers will compare two groups-one receiving active brain stimulation and one receiving a sham (placebo) stimulation-to see if the active device provides greater improvements in symptoms. Participants will: 1. Use the NettleEndo device at home for 20 minutes per session, five times per week for 12 weeks 2. Be randomly assigned to receive either real or sham stimulation through the device 3. Complete daily and weekly symptom ratings through a mobile app 4. Wear an optional fitness tracker to collect data on sleep, movement, and heart rate variability 5. Be followed for 60 days after completing the intervention to monitor longer-term effects All activities are completed remotely using a smartphone app. Participants can contact the study team with questions at any time. The study is double-blind, meaning neither participants nor the researchers assessing outcomes will know who received active or sham treatment until the end of the trial.
Recruiting
Online Trial
Alethios, Inc.Nirav Shah, MD, MPHSamphire Group, Inc.
Image of University of California, San Diego in La Jolla, United States.

Lidocaine for Pain Control in Birth Control

18 - 50
Female
La Jolla, CA
The goal of this research study is to learn more about how different uses of a numbing medication might affect pain levels while getting an IUD placed. The investigators are also studying participants opinions of their clinicians' empathy. The investigators are inviting patients who arrive at their clinic visit seeking an IUD. Usually, at University of California, San Diego (UCSD), for patients who have never delivered a baby, clinicians use a buffered paracervical block for before IUD placement. The purpose of this research study is to investigate whether a "buffered" (2 cc of sodium bicarbonate, 18 cc of 1% lidocaine) paracervical block (numbing medication given on both sides of the cervix) is effective in reducing pain during IUD placement in individuals with prior C-sections, the difference between buffered and unbuffered for nulliparous patients, and whether a medicated gel reduces pain with the paracervical block.
Recruiting
Paid Trial
University of California, San DiegoSheila K Mody, MD, MPH
Have you considered Briellyn clinical trials? We made a collection of clinical trials featuring Briellyn, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security